The locally active ligand peptides, mediators, receptors and signalling pathways of the haematopoietic BM (bone marrow) autocrine/paracrine RAS (renin-angiotensin system) affect the essential steps of definitive blood cell production. Haematopoiesis, erythropoiesis, myelopoiesis, formation of monocytic and lymphocytic lineages, thrombopoiesis and other stromal cellular elements are regulated by the local BM RAS. The local BM RAS is present and active even in primitive embryonic haematopoiesis. ACE (angiotensin-converting enzyme) is expressed on the surface of the first endothelial and haematopoietic cells, forming the marrow cavity in the embryo. ACE marks early haematopoietic precursor cells and long-term blood-forming CD34 + BM cells. The local autocrine tissue BM RAS may also be active in neoplastic haematopoiesis. Critical RAS mediators such as renin, ACE, AngII (angiotensin II) and angiotensinogen have been identified in leukaemic blast cells. The local tissue RAS influences tumour growth and metastases in an autocrine and paracrine fashion via the modulation of numerous carcinogenic events, such as angiogenesis, apoptosis, cellular proliferation, immune responses, cell signalling and extracellular matrix formation. The aim of the present review is to outline the known functions of the local BM RAS within the context of primitive, definitive and neoplastic haematopoiesis. Targeting the actions of local RAS molecules could represent a valuable therapeutic option for the management of neoplastic disorders.
INTRODUCTION
We first proposed the concept that there exists a local haematopoietic RAS (renin-angiotensin system) in the BM (bone marrow) [1, 2] . The main RAS molecules, including renin, angiotensinogen, angiotensin receptors and ACE (angiotensin-converting enzyme), are all present in the BM micro-environment [3] . Locally active BM RAS affects critical steps of physiological and pathological blood cell production via autocrine, paracrine and intracrine pathways [4, 5] . Haematopoietic niche [6] , myelopoiesis [7] , erythropoiesis [8] , thrombopoiesis [9] and the development of other cellular lineages [6, [10] [11] [12] are regulated by the biological actions of local BM RAS peptides. The local RAS [4, 5] Abbreviations: ACE, angiotensin-converting enzyme; ACEI, ACE inhibitor; AcSDKP , N-acetyl-Ser-Asp-Lys-Pro; AGM, aorta-gonad mesonephros; AML, acute myeloid leukaemia; Ang-(1-7), angiotensin-(1-7); AngI etc., angiotensin I etc.; AGTRAP , AngII-receptor-associated protein; APC, antigen-presenting cell; ARB, AngII receptor blocker; AT 1 R etc., angiotensin type 1 receptor etc.; BM, bone marrow; C/EBPα, CCAAT/enhancer-binding protein α; CCL, CC chemokine ligand; CGRP , calcitonin gene-related peptide; D, deletion; EPO, erythropoietin; ERK, extracellular-signal-regulated kinase; GABARAP , γ -aminobutyric acid-receptor-associated protein; I, insertion; JAK, Janus kinase; JNK, c-Jun N-terminal kinase; KO, knockout; LSK, Lin − Sca1 + c-Kit + ; mAb, monoclonal antibody; M-CSF, macrophage colony-stimulating factor; MMP , matrix metalloproteinase; NF-κB, nuclear factor κB; NK, natural killer; NK1, neurokinin 1; NUP98, Nucleoporin 98; HOXA9, NUP98-homeobox A9; PI3K, phosphoinositide 3-kinase; PLZF, pro-myelocytic zinc-finger protein; PRR, (pro)renin receptor; PRV, polycythaemia ruba verae; PV, polycythaemia verae; RAS, renin-angiotensin system; RER, renin/prorenin receptor; RIS, retroviral integration site(s); SP , substance P; STAT, signal transducer and activator of transcription; TBI, total body irradiation; TNF, tumour necrosis factor; UCB, umbilical cord blood; UICC, Unio Internationale Contra Cancrum; VEGF, vascular endothelial growth factor.
Correspondence: Professor Yavuz Beyazit (email yavuzbeyaz@yahoo.com).
is also active in the BM stromal niche for crucial regulation of haematopoietic functions [3, 13] . AT 1 R and AT 2 R (angiotensin type 1 and type 2 receptors respectively), and the inhibitory tetrapeptide AcSDKP (N-acetyl-Ser-Asp-Lys-Pro) are present in the BM stromal micro-environment. The major RAS effector mediator AngII (angiotensin II) exerts its haematopoietic effects by activating angiotensin receptors, primarily AT 1 Rs and AT 2 Rs, within the BM micro-environment [4, 5] . ACE (CD143) has been implicated in enhancing the recruitment of primitive stem cells into S-phase by degrading AcSDKP [9, [14] [15] [16] [17] . Moreover, stimulation of AT 1 Rs/AT 2 Rs by AngII, the principle effector molecule of the RAS, exerts stimulatory/inhibitory action on the JAK/STAT (Janus kinase/signal transducer and activator of transcription) pathway, which is directly linked to the physiological functions of erythropoietin, thrombopoietin and other haematopoietic cytokines during normal haematopoiesis and in myeloproliferative neoplasms [9, [18] [19] [20] . The local RAS is effective even at the stage of primitive embryonic haematopoiesis [21] [22] [23] [24] .
The RAS affects numerous biological events that are important for the formation and function of blood cells [25] . Apoptosis [26] , cellular proliferative events [18, 27, 28] , mobilization [29] , angiogenesis [30] , fibrosis within the cytokine network [31] and many other essential pathobiological events are affected by the critical RAS molecules [4, 5, 32, 33] . Haematological clonal neoplastic disorders are characterized by excessive production of malignant cells, as well as disordered apoptosis, impaired differentiation, pathological signalling and cancer angiogenesis [34] [35] [36] [37] [38] [39] . Neoplastic malignant blood cells are derived from leukaemic stem cells within a complex series of pathological proliferative steps. There is preliminary evidence that the local BM RAS could affect neoplastic tumoral blood cell production [34] [35] [36] [40] [41] [42] [43] [44] [45] . The prominent functions of the local RAS in primitive embryonic haematopoiesis [21] [22] [23] [24] support further the hypothesis that the local autocrine BM RAS could be active in neoplastic haematopoiesis. Table 1 summarizes an overview of the current findings implying the existence of a local RAS in primitive neoplastic haematopoiesis.
The aim of the present review is to outline the situation and function of the local BM RAS within the context of primitive, definitive and neoplastic haematopoiesis. Critical RAS mediators such as renin [44] , ACE [35] , AngII [46] and angiotensinogen [36] have already been identified in leukaemic blast cells. RASmodulating agents could also alter the pathological formation of neoplastic blood cells [47] . Elucidation and future dissection of the status of the local BM RAS in leukaemogenesis is not only an academic issue, but also represents a clinically relevant basic research area [4, 5] . For instance, a pharmacological form of the peptide Ang-(1-7) [angiotensin- (1) (2) (3) (4) (5) (6) (7) ] is already in Phase I/II clinical trials for the modulation of the local BM RAS in distinct disease states [33, 48, 49] .
THE LOCAL BM RAS IN POST-NATAL DEFINITIVE HAEMATOPOIESIS
Haematopoietic BM gives rise to all circulating blood cells and is a highly organized complex system. HSCs (haematopoietic stem cells) and committed haematopoietic precursors interact with local BM micro-environmental stromal cells, providing the majority of essential growth factors to maintain the regulation of haematopoietic cell development. Dynamic events of post-natal haematopoiesis within the BM microenvironment are regulated by the production or degradation of numerous soluble factors, such as cytokines and bioactive peptides. The local BM RAS mediates the complicated network of BM haematopoiesis in an autocrine/paracrine/intracrine fashion. The growth, production, proliferation and differentiation of blood cells are affected by the haematopoietic RAS [1, 4, 5] . AT 1a Rs are present in CD34 + haematopoietic cells and stimulate the proliferation of both BM and UCB (umbilical cord blood) haematopoietic progenitors in physiological or pathological states [32] . ACE, converting AngI (angiotensin I) into AngII, has a role in many aspects of haematopoiesis [7, 15, 21, 50, 51] . A pan-lineage proliferative effect of AngII has been demonstrated. Exogenous AngII facilitates colony formation from HSCs to CFU-GMs (colony-forming unitgranulocyte/macrophages) and CFU-GEMMs (colony-forming unit-granulocyte/erythroid/macrophage/megakaryocytes) under a pan-myeloid condition [12] . AngII specifically regulates TNF (tumour necrosis factor)-α synthesis and release from BM stromal cells, acting on monocytic lineages [52] . Richmond and co-workers [53] provided the basis for further understanding the role of AngII in the regulation of both normal and dysfunctional haematopoiesis. Locally produced AngII affects arachidonic acid release within the BM micro-environment. Arachidonic acid, upon its release by AngII, can enter the BM cellular compartment and act as a signalling molecule to influence proliferation or apoptosis of haematopoietic precursors. Arachidonic acid and its eicosanoid metabolites induced by AngII are involved in multiple pathways of the haematopoietic control mechanism [53] . Critical formation steps of distinct lineages of blood cells, such as the myeloid cells and erythroid elements, are subject to the pathobiological activities of the local BM RAS [1, 4, 5] .
The local BM RAS regulates peptides for haematopoiesis. ACE releases AngII from AngI and degrades the bioactive SP (substance P), AcSDKP and Ang-(1-7). Moreover, SP is released from the nerve endings projecting to the BM in the vicinity of micro-environmental stroma. RAS peptides are produced from the BM tissue through the contribution of both stromal cells and haematopoietic cells. Both stromal cells and haematopoietic cells are equipped with AT 1 Rs and NK1 (neurokinin 1) receptors, which mediate the action of AngII and SP respectively. Mas, the receptor for Ang-(1-7), has been detected in the BM stroma as well [12] (Figure 1 ).
Myelopoiesis and white blood cells
ACE, within the context of the local BM RAS, affects normal myelopoiesis. ACE-KO (knockout) mice exhibited prominent abnormalities in myelopoiesis characterized by increased BM myeloblasts and myeloid cells, as well as extramedullary myelopoiesis. AngII, through the AT 1 R, also acts to boost myeloid differentiation and functional maturation. The myelopoietic effects of ACE and AngII are evident at the HSC level, extending to the committed myeloid and erythroid lineages [7] . Leucocytes expressing the angiotensinogen gene, synthesizing and releasing angiotensinogen with the capability to generate angiotensin, represent another clue for local RAS-modulating effects on myelopoiesis [54] .
Lin et al. [7] demonstrated the status of ACE in myelopoiesis in a series of elegant experiments in their ACE-KO mice model. They quantified BM cell populations and found that the numbers of neutrophils (band and segmented cells) and erythroid elements are 37 % reduced in ACE-KO mice in comparison with the wild-type mouse. Moreover, myeloblasts increased 2.2-fold, eosinophils 2.3-fold and immature myelocytes 2.5-fold in the ACE-KO mice. Likewise nucleated erythroid precursors decreased to 77 % of control values, leading to anaemia in the animals [7] . Splenomegaly with extramedullary haematopoiesis, consisting of immature myeloid elements, further complicated the clinical 
Ang-(1-7) increased early mixed progenitors, erythroid progenitors, megakaryocytes and BM myeloid progenitors Ang-(1-7) in accordance with AngII seems to be a pan-haematopoietic cytokine, stimulating the critical steps of haematopoiesis and myelopoiesis Sinka et al. [22] (2012) ACE is expressed in all presumptive and developing blood forming tissues of the human embryo and fetus: para-aortic splanchnopleura, yolk sac, AGM, liver and BM ACE could identify embryonic mesodermal precursors responsible for definitive haematopoiesis and is involved in the regulation of human blood formation Figure 1 The Local BM ACE regulates peptides for haematopoiesis Systemically, AngI, AngII, AcSDKP and Ang-(1-7) are produced in other tissues and shipped to the BM through circulation, whereas SP is released from the nerve endings projecting to the BM (in the vicinity of stroma). These peptides are also produced from BM tissue by the contribution of both stromal cells and haematopoietic cells. ACE releases AngII from AngI and degrades the bioactive SP , AcSDKP and Ang-(1-7). Both stromal cells and haematopoietic cells are equipped with AT 1 Rs and NK1 receptors, which mediate the actions of AngII and SP respectively. AcSDKP is known to act on haematopoietic cells, but its receptor has not been identified. Mas, the receptor for Ang-(1-7), can been detected in BM. These peptides thus can either directly stimulate haematopoietic cells or perform their actions through stromal cells. This Figure was modified with kind permission from Xiao Z. Shen [12] .
picture of the ACE-KO mice. The AngII level was 10-fold lower in these ACE-KO mice. The myeloid effects of ACE and AngII could be ascribed, in part, to the up-regulation of the central transcription factor of myelopoiesis C/EBPα (CCAAT/enhancerbinding protein α) [7] . Macrophages derived from ACE-KO mice had depressed C/EBPα expression, and AngII supplementation to ACE-KO mice rescued myeloid C/EBPα expression [12] . Therefore the local BM RAS affects haematopoiesis both by altering internal signals of transcription factors regulating gene expression and by mediating external signals from growth factors secreted from the BM micro-environmental haematopoietic and stromal cells. ACE, as a cell-surface zinc metallopeptidase, cleaves the negative physiological haematopoietic regulator AcSDKP into its inactive form in the BM micro-environment [15] . Therefore ACE hyperfunction may lead to the acceleration of AcSDKP metabolism, which in turn would lower its levels in the BM microenvironment, finally removing the antiproliferative effects of the peptide on haematopoietic cells and blasts. The haemoregulatory tetrapeptide AcSDKP reversibly prevents the recruitment of pluripotent HSCs and normal early haematopoietic progenitors into S-phase of the cell cycle by keeping them quiescent [14, 16, 34] .
Kinin B 1 -receptor-KO mice were suggested to be an experimental model for ACE hyperfunction. Oliveira et al. [17] examined BM cell populations involved in the ACE expression and the role of AcSDKP in the ACE activity in this murine BM cell proliferation model. They demonstrated a decrease in the
+ , CD3 + and primitive population LSK (Lin − Sca1 + cKit + ) cells in the B1-KO mice. The authors used the ACE substrate Abz-YRK(Dnp)P-OH [o-aminobenzoic acid-Phe-ArgLys(DNP)-Pro-OH] and observed an increase in B1-KO longterm BM culture (LTBMC) ACE activity in relation to the wildtype cultures. However, the biological significance of those findings remain to be elucidated [17] .
Ang-(1-7) is a component of the RAS, stimulating haematopoietic recovery after myelosuppression. Ang-(1-7) can be formed directly from the major RAS peptide AngII by the actions of the enzyme ACE2 and also from the AngI peptide. Mas receptors present in the BM micro-environment mediate the proliferative effect of Ang-(1-7) on HSCs [32] . Rodgers and co-workers [55] tested the ability of the Ang-(1-7) peptide to improve radiation-induced haematopoietic injury after TBI (total body irradiation) in an animal model. In their study, daily administration of subcutaneous Ang-(1-7) after radiation exposure improved survival (from 60 % to 92-97 %) and reduced radiation-induced thrombocytopenia (up to 2-fold) after TBI. Moreover, Ang-(1-7) increased early mixed progenitors (3-5-fold), erythroid progenitors (2-fold), megakaryocytes (2-3-fold), and BM myeloid (3-6-fold) progenitors. Therefore Ang-(1-7) seems to be a panhaematopoietic cytokine stimulating the critical steps of haematopoiesis and myelopoiesis [27, 29, 33, 48, 49, 55, 56] . Ang- (1-7) is now considered as a drug candidate for the modulation of local BM RAS-mediated haematopoiesis in a variety of clinical disorders [33, 48, 49] . The emerging ACE2/Ang-(1-7)/Masreceptor-axis-oriented drugs are of particular interest [32] .
AngII, through the BM cellular AT 1 Rs, regulates the differentiation/proliferation of monocyte lineage cells to exert proatherogenic actions in the cardiac micro-environment [52, 71] . AT 1 R signalling is required for macrophage development. On the basis of experiments performed by Tsubakimoto et al. [52] in BM chimaeric apoE (apolipoprotein E) − / − mice re-populated with AT 1 R-deficient (Agtr1 − / − ) or wild-type (Agtr1 + / + ) BM cells, AngII regulates the expression of c-Fms in HSCs and monocyte lineage cells through BM stromal cell-derived TNF-α to promote M-CSF (macrophage colony-stimulating factor)-induced differentiation/proliferation of monocyte lineage cells. M-CSFinduced differentiation from HSCs (LSK) to pro-monocytes (CD11b high Ly-6G low ) was markedly reduced in HSCs from AT 1 Rdeficient Agtr1
− / − mice in their experiments [52] .
Erythropoiesis and red blood cells
Inactivation of the gene encoding mouse ACE results in anaemia in adult animals. This anaemia is corrected by AngII, demonstrating the involvement of AngII in definitive erythropoiesis [57, 58] . AngII enhances erythropoiesis via the stimulation of erythroid progenitor cells and increases haematopoietic progenitor cell proliferation [8, [59] [60] [61] . Kato and co-workers [8] demonstrated that transgenic mice carrying both the human renin and human angiotensinogen genes displayed persistent erythrocytosis. They introduced both transgenes into the AT 1a R-null background and found that the haematocrit level in the compound mice was restored to the normal level. They conducted BM transplantation experiments and clarified that AT 1a Rs on BMderived cells were dispensable for RAS-dependent erythrocytosis [8] . AngII could increase EPO (erythropoietin) levels, and EPO mediates the effects AT 1a Rs in erythropoiesis [8] . The data on PRR [(pro)renin receptor] and erythropoiesis are very limited. Only the study by Kaneko et al. [59] disclosed the expression of PRR in BM erythroid cells and a dynamic increase in PRR expression by IFN (interferon)-γ , an inflammatory cytokine suppressing erythropoietin production and erythropoiesis. PRR is constitutively expressed in erythroid cells independently of their differentiation states. When bound to (pro)renin, PRR leads to the non-proteolytic activation of the peptide and directly activates MAPK (mitogen-activated protein kinase) ERK (extracellularsignal-regulated kinase) 1/2 signalling pathways [59] . Therefore local BM RAS-induced enhanced eythropoiesis seems to be regulated in an autocrine and intracrine manner. The PRR is a relatively new element in the RAS and thus findings are sparse [62] . The primary localization of the human RER (renin/prorenin receptor) is in the intracellular perinuclear zone. Furthermore, a transcription factor, PLZF (pro-myelocytic zinc-finger protein), was identified as a direct protein interaction partner of the renin receptor and, following the activation of RER by renin, PLZF is translocated from the cytoplasm to the nucleus, providing positive or negative regulation of target genes [63] . The regulation of c-kit expression involves transcriptional control by PLZF in CD34 + cells and early erythropoiesis [64] . PLZF is also an important AT 2 R-binding protein in mediating AngII-induced cellular effects through an AT 2 R-dependent signalling pathway. The AngII/AT 2 R/PLZF/GATA4 signalling pathway may modulate the AngII-induced pathological effects [65] . These very preliminary findings about the interactions of PRR, PLZF, AngII and erythropoiesis need to be tested in future experiments.
Savary et al. [66] indicated the presence and function of the local RAS in primitive embryonic erythropoiesis located in the yolk sac of the chicken embryo in the vicinity of blood islands. ACE, renin, angiotensinogen and angiotensin receptors are present in the yolk sac endoderm, concomitantly with the differentiation of blood islands in the adjacent yolk sac mesoderm. ACEIs (ACE inhibitors) and ARBs (AngII receptor blockers) decreased erythroblast proliferation induced by RAS in this embryonic animal model. Therefore the local autocrine RAS is active in the modulation of both primitive and definitive erythropoiesis. RAS inactivation may confer susceptibility to the haematocritlowering effects of ACEIs or ARBs via interfering with this BM cellular autocrine RAS network [67] .
RAS can also affect pathological and neoplastic erythropoiesis. AT 1 R expression in erythroid progenitors has been implicated in the pathogenesis of post-renal transplant erythrocytosis [60] . Increased local synthesis of the major RAS components has also been identified by demonstrating corresponding mRNAs in the BM in PV (polycythaemia verae). Therefore upregulation of the local BM RAS in autonomous neoplastic clonal erythropoiesis of PV has been suggested [40] .
Thrombopoiesis and platelets
The RAS member AGTRAP (AngII-receptor-associated protein) is active in haematopoietic cell proliferation and survival and points to its synergistic effect with the proliferation promoting function of the thrombopoietin receptor Mpl [9] . The Mpl protooncogene plays a basic role in megakaryocytic development and platelet production, as well as performing a substantial function in HSC homoeostasis and self-renewal [68] .
The results on angiotensin peptides in thrombopoiesis is very limited. The only study is by Kwiatkowski et al. [9] , who performed retroviral insertional mutagenesis using an MSCV (murine stem cell virus)-based vector coding for a drug-dependent dimerizable fusion protein that contains the cytoplasmic domain of Mpl. They used the vector construct to transduce the human leukaemia cell line K562, which also includes all of the RAS elements [45] . In the absence of Mpl signalling, the cells underwent erythroid differentiation and died. Cells that acquired proliferative advantage and were dependent on Mpl function were expected to point to mutations synergistic with Mpl signalling. Cloning of RIS (retroviral integration site) from the selected populations could allow the identification of over-represented clones. RIS from the over-represented clones pointed to candidate Mpl co-operating genes. AGTRAP, a member of RAS, was identified among the candidate genes. Kwiatkowski et al. [9] also tested the function of AGTRAP in haematopoietic cells. In their experiments, AGTRAP protein was overexpressed in K562 cells and in K562 cells driven by Mpl signalling. The survival of Mpl-dependent K562 cells overexpressing AGTRAP was still dependent on Mpl signalling and on JAK2 function. [9] .
Platelets expressing AT 1 Rs contribute to thrombogenic and inflammatory responses [69] . AngII, through its receptors, has in vivo platelet-activating effects, and markers of platelet secretion are also significantly increased [70] . The clinicopathological relevance of these findings may be evident. AngII elicited a doseand time-dependent increase in platelet-leucocyte-endothelial cell interactions in the cerebral venules, which included rolling platelets, adherent platelets on the leucocytes and the endothelial cells, rolling leucocytes and adherent leucocytes [69] .
Formation of other blood cell lineages: dendritic cells, mast cells, T-cells, monocytes, macrophages and APCs (antigen-presenting cells)
Multiple lines of evidence indicate that the local RAS is active in haematopoietic cell proliferation and differentiation, which also leads to the production and function of distinct blood cell lineages, such as dendritic cells, mast cells, T-cells, monocytes, macrophages and antigen-presenting cells [4, 5] . ACE degrades SP present in the BM micro-environment, lymphoblasts and lymphocytes by cleaving a C-terminal dipeptide or tripeptide [12] .
The local RAS is also expressed in the cellular compartment of the immunohaematological system, such as on APCs. AT 1 Rs are expressed on both T-cells and APCs [71] . AT 1 Rs are required for the normal development and function of dendritic cells [72] [73] [74] . Dendritic cells are highly specialized APCs with a unique ability to activate resting T-cells. AngII, acting through the AT 1 R, facilitates dendritic cell development, whereas signalling through the AT 2 R counteracts AT 1 R signalling in this haematological line [12, 74] . Nahmod et al. [74] have shown the effects of AngII, AT 1 Rs and AT 2 Rs in dendritic cell differentiation from monocytes in the BM. Pharmacological blocking of the AT 1 R during GM-CSF (granulocyte/macrophage colony-stimulating factor)-stimulated culture hampered dendritic cell maturation, as indicated by the decreased expression of surface maturation markers, the reduced efficiency of endocytosis and the decreased ability to stimulate allogeneic T-cell proliferation. In contrast, AT 2 R blockade or AngII addition during culture had the opposite effect and stimulated progenitors to obtain the functional activities of the dendritic cells [74] . AT 1a R-deficient BM-derived dendritic cells produce higher levels of MCP-1 (monocyte chemoattractant protein-1) [73] . Another study by the same group [72] reported that the absence of AT 1 Rs results in the generation of dendritic cells with major alterations in their phenotypic and functional immunohaematological properties. They suggested that AngII stimulates dendritic cell differentiation and function in an autocrine/paracrine manner by signalling via AT 1 Rs to contribute to perpetuating immuno-inflammatory responses [72] .
The effects of the RAS on dendritic cells and APCs seem to be clinically relevant for the pathogenesis of immuno-inflammatory disorders. Quantitative RT (reverse transcription)-PCR analyses by Stegbauer et al. [71] showed the up-regulation of renin, ACE and AT 1 R in the immune system, including APCs in the myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. They demonstrated that the local RAS is up-regulated during autoimmune inflammation in the immune system and exerts its functions mainly via the AT 1 R in an autocrine/paracrine/intracrine manner by modulating APC populations and governing the expression of chemokines. Blockade of AT 1 Rs significantly reduced the number of CD11b + or CD11c + APCs in immune organs and in the inflamed spinal cord. Likewise, AT 1 R blockade impaired the expression of CCL (CC chemokine ligand)2, CCL3, and CXCL (CXC chemokine ligand)10, and reduced CCL2-induced APC migration [71] .
Pre-formed AngII as a potent growth factor is present and released by human mast cells. The presence of pre-formed AngII and gene expression of the RAS system were detected in human mast cells by Hara et al. [10] . The release and synthesis of AngII in mast cells was regulated by CGRP (calcitonin gene-related peptide). CGRP induced the release of AngII and increased angiotensinogen mRNA in a human mast cell line. Mast cells are, therefore, considered as a mobile RAS regulated by neural activity. As the number of mast cells increases, they may significantly contribute to the production of AngII in the target organ, such as the heart [10] .
THE LOCAL RAS IN PRIMITIVE EMBRYONIC HAEMATOPOIESIS
The human embryo represents a model for the production of the first multipotent haematopoietic cells that constitute the stem cells of the fetal and post-natal blood systems. Primitive haematopoietic cells during all stages of haematopoietic ontogeny include UCB, the fetal liver, embryonic para-aortic splanchnopleura and primitive haematopoietic cells in the AGM (aorta-gonad mesonephros) region [21] .
Previous studies [21] [22] [23] [24] have focused on the status of ACE within the context of the local RAS, the earliest human embryonic HSCs [75] and the developmental sequence underlying the ontogeny of human blood cells. The local RAS regulates the genesis and function of the haematopoietic system starting from embryonic life [23] . A mAb (monoclonal antibody) named BB9, raised initially to human BM stromal cells, recognizes the somatic isoform of ACE as an HSC marker. It exhibits reactivity with primitive haematopoietic cells at all stages of haematopoietic ontogeny, including in the UCB and fetal liver [21] . Human embryonic stem-cell-derived ACE + CD45 − CD34 + − cells are the common yolk-sac-like progenitors for not only the endothelium, but also both primitive and definitive human lymphohaematopoietic stem cells (Figure 2 ) [24] .
During embryonic development, multi-lineage HSCs/ progenitor cells are derived from specialized endothelial cells, which are termed the haemogenic endothelium, within the yolk sac, placenta and aorta [76] . Jokubaitis and co-workers [21] have reported that ACE, as recognized by mAb BB9, is a marker of primitive haematopoietic cells at all stages in the ontogeny of the human haematopoietic system. In their experiments, BB9/ACE was expressed during the development of the human haematopoietic system. BB9 identified the somatic form of ACE and SCID (severe combined immunodeficiency) mouse repopulating cells, and the perturbation of RAS signalling altered the proliferation of primitive haematopoietic progenitors [21] . Zambidis et al. [24] have demonstrated that the RAS is a pivotal regulator of human haemangioblast differentiation. They showed that AT 1 R and AT 2 R are expressed on human haemangioblasts. Furthermore, differentiation of haemangioblasts into either haematopoietic or endothelial progenitors can be influenced by modulating the signalling through these two main AngII-binding receptors [24] . In their studies, a clonogenic human embryonic stem-cell-derived haemangioblast expressing surface ACE initiated both primitive and definitive yolk-sac-like haematopoiesis. ACE expression prospectively identified all multipotent progenitors of embryonic haematopoiesis and the RAS regulated the expansion and differentiation of human embryonic haemangioblasts. Captopril inhibition of ACE enzymatic activity severely inhibited human haemangioblast colony expansion. Therefore the authors [24] suggested that human angiohaematopoiesis initiates from an ACE − haemangioblastic progenitor of primitive and definitive haematopoiesis under the functional activities of the local RAS [24] .
Sinka et al. [22] searched for the presence of ACE in the earliest pre-AGM stages of human intra-embryonic angiohaematopoiesis. In their study, in the earliest stages of human development, the haematopoietic potential in the splanchnopleura is restricted to emerging CD34 − ACE + precursors. ACE + CD34 − CD45 − mesodermal precursors migrating from the splanchnopleura toward the ventral aorta gave rise to the CD34 + intra-aortic haematopoietic clusters. ACE is expressed in all of the blood-forming tissues in the human embryo, including the yolk sac, splanchnopleura, aorta, fetal liver and BM. ACE expression has functions in the maintenance of embryonic haematopoiesis [22] . These results also confirmed our hypothesis that there is a local RAS in the BM [1, 2] . Sinka and co-workers [22] [22] . Emerging haemangioblasts in the yolk sac or AGM may be directed to differentiate by the HSC niche [21] [22] [23] [24] . Antagonistic competition between AT 2 R and AT 1 R for AngII binding on emerging haemangioblasts directs their development into either haematopoietic progenitors or alternatively into vascular endothelial networks. AT 1 R/AT 2 R-regulated stem cell proliferation may be a generalized phenomenon in primitive and definitive haematopoiesis. Therefore manipulation of angiotensin receptor signalling could be an important strategy for the expansion of multipotent haematopoietic progenitors from primitive HSCs.
There are some hypotheses regarding the local BM RAS and the cellular differentiation function of HSCs, called 'stem cell plasticity', but these lack solid data [19] . Post-natal HSCs have a tremendous capacity for cellular differentiation in distinct tissues. This HSC function mimicking embryonic haematopoiesis is dependent on, and responsive to, the specific signals present in the local tissue micro-environment. AngII and 5-azacytidine can promote the proliferation and differentiation of BM mesenchymal stem cells into cardiomyocyte-like cells [77] . There is a relationship between angiotensin and transdifferentiation of epithelial cells into fibroblasts. The local embryonic RAS also plays a fundamental role in kidney development. The process of haemovasculogenesis closely related to the functions of the local RAS highlights the capacity of the kidney to produce its own blood cells simultaneously with in situ blood vessel formation [78] . Further investigations should focus on testing these hypotheses in distinct experimental settings.
RAS IN THE BASIC PATHOBIOLOGICAL EVENTS OF CARCINOGENESIS AND CANCER
Carcinogenesis, the development of cancer, depends upon dysregulation in a complex series of neoplastic pathobiological events. The role of the RAS in cancer represents a model for a better understanding of the place of local BM RAS in haematological neoplastic disorders. The imbalance between cellular proliferation/differentiation and apoptosis associated with immunopathological alterations and genomic dysregulation due to somatic and/or germline mutations, neoplastic intracellular signalling due to oncogenic autocrine/paracrine/intracrine effects, tumour angiogenesis, fibrosis in the tumour microenvironment, and pathological mobilization of tumoral cells could take place in the complicated pathological network of carcinogenesis [50, 79, 80] .
The local RAS is one of the crucial components in the tumour micro-environment and plays an important role in the tumour metabolism, survival, angiogenesis and invasion processes [81] . The local tissue RAS influences tumour growth and metastases in an autocrine and paracrine fashion, via the modulation of numerous carcinogenic events, such as angiogenesis, apoptosis, cellular proliferation, immune responses, cell signalling and extracellular matrix formation. For instance, locally formed AngII in intrahepatic cholangiocarcinoma tissues plays a role in the proliferation and activation of cancer cells [82] . Potential manipulation of the local RAS with many enzymes, peptides and feedback mechanisms can even represent a therapeutic target for the clinical management of cancer [50, 79, 80] .
AngII induces DNA damage in the form of single-and doublestrand breaks. The AT 1 R-specific ARB candesartan was able to prevent all types of injury caused by AngII, proving the DNA damage to be mediated by AT 1 Rs [83] . The ACEI enalapril, together with aspirin, could delay the progression of pancreatic tumours and partially inhibit the formation of invasive murine pancreatic cancer in a genetically engineered mouse cancer model [84] . Likewise, losartan improves the efficacy of systemically administered nanotherapeutics to highly fibrotic solid tumours, such as pancreatic adenocarcinomas [85] .
RAS and apoptosis
The biological activities of AT 1 Rs and AT 2 Rs and pathological alterations in their signalling could influence whether cancer cells undergo apoptosis or survive in response to RAS activation [80] . There are conflicting reports in the literature regarding apoptosis and RAS interactions [26, 28, 80] . Signalling through AT 2 Rs is invariably linked to the promotion of apoptosis, whereas activation of AT 1 Rs by AngII in malignant cells can enhance pro-survival anti-apoptotic signalling [86] . AT 1 R signalling interacting with the AT 2 R and/or the Mas receptor produces multiple regulatory, biological, inflammatory, angiogenic, proliferative and apoptotic actions. Hyperactivity of the RAS axis produces apoptosis in the cardiac micro-environment [86] . The role of angiotensin receptor interactions in cellular apoptosis have been studied in cardiomyocyte physiology [87] . Staining for caspase 3, an apoptotic marker, indicated that overexpression of AT 1 Rs as well as AT 2 Rs resulted in cardiomyocyte apoptosis with alterations in the expression of the apoptotic molecules annexin V, Bax and Bcl2. AT 1 R-mediated cardiomyocyte apoptosis may be partially mediated by the up-regulation of endogenous AT 2 Rs. AT 2 R overexpression induced cardiomyocyte apoptosis via iNOS (inducible NO synthase) up-regulation [87] . Ghrelin may play an antagonistic role in AngII-induced cardiomyocyte apoptosis via decreasing AT 1 R expression and inhibiting the activation of the endoplasmic reticulum stress pathway [88] . RAS blockade normalized renal ACE2 expression and urinary Ang-(1-7) levels, prevented tubular apoptosis, and inhibited pro-fibrotic and proapoptotic gene expression in mouse models, although some other studies have shown that ACEIs and ARBs increase Ang-(1-7) levels [89] . RAS signalling has been implicated in enhanced survival and increased proliferation of cancer cells. Pro-apoptotic mechanisms of the RAS are mediated through the AT 2 R or the Mas receptor, whereas anti-apoptotic actions are linked to AT 1 R signalling [80] . The RAS has been linked to the inhibition of ERK signalling and the activation of cell death receptors, which leads to apoptosis. Meanwhile, the AT 1 R activates mitogenic signalling pathways, including MAPK or PI3K (phosphoinositide 3-kinase) pathways, and leads to the downstream activation of transcription factors, including NF-κB (nuclear factor κB), which is responsible for the generation of numerous anti-apoptotic proteins, such as Bcl-X L , survivin and Bcl2 [80] . Although the effects of RAS on the apoptotic process do not seem to be homogenous, those pathobiological findings in relation to apoptosis underline the role of the local RAS in carcinogenesis.
RAS and cellular proliferation-differentiation
The RAS can enhance both the proliferation and differentiation of progenitor cells. Cellular differentiation was found to be associated with an increase in cellular renin, AngII production, AT 2 R expression and a concomitant decrease in angiotensinogen and ACE expression [90] . AngII, through AT 1 Rs, can induce DNA synthesis, augment the generation of superoxide and activate phosphorylation of the critical oncogenic signalling pathways JAK/STAT3 and p38 MAPK [91] . On the other hand, the AT 2 R functions in the inhibition of cellular proliferation [92] . Angiotensin peptides have a role in pathological cellular proliferation during cancer development. Angiotensin-generating cascades control developmental processes and homoeostasis. For instance, AngII can stimulate the proliferation of breast cancer growth via activation of the up-regulated AT 1 R [93] . The promotional effects of AngII on neoplastic proliferation are dependent upon alterations in cell-cycle machinery and downstream AT 1 R signalling events. Activation of the Ras/Raf/MAPK pathway and the transcription factors NF-κB and CREB (cAMP-responseelement-binding protein) takes place in malignant cellular proliferation induced by AngII. ARBs might suppress the proliferative effects of angiotensin peptides. Irbesartan, a typical ARB, significantly altered p53, PCNA (proliferating-cell nuclear antigen) and cyclin D1 expression, which was also influenced by activated the AT 1 R in AT 1 R + MCF-7 breast cancer cells in vitro [93] .
RAS and intracellular signalling
The local tissue RAS includes an intracellular system involved in cell signalling and function. Functional intracellular or nuclear RAS may have an important role in the pathobiology of the RAS. AngII, via AT 1 Rs, can induce G-protein-and non-G-protein-related signalling pathways. MAPKs [ERK 1/2, JNK (c-Jun N-terminal kinase) and p38 MAPK], receptor tyrosine kinases [PDGF (platelet-derived growth factor), EGFR (epidermal growth factor receptor), IRS-1 (insulin receptor substrate-1)] and non-tyrosine receptor kinases [Src, JAK/STAT and FAK focal adhesion kinase)] are involved in local intracellular RAS functions. AngII also promotes the association of scaffolding proteins, such as paxillin, talin and p130Cas, leading to focal adhesion and extracellular matrix formation. These signalling cascades lead to cellular growth, cell migration and disease progression [28] . For instance, the JAK/STAT pathway, an important intracellular signal transduction system for numerous haematopoietic growth factors, serves as a point of cross-talk between the components of the locally present RAS in the BM and neoplastic haematopoietic disorders [18, 20, 52] . Intracellular expression of all three predominant angiotensin receptor subtypes is evident in the nuclear compartment [94, 95] . The AT 1 R is coupled to the generation of ROS (reactive oxygen species) through the activation of PI3K signalling, whereas AT 2 Rs and Ang-(1-7) receptors stimulate NO formation [94] . GABARAP [GABA (γ -aminobutyric acid) receptor-associated protein] serves as a trafficking protein for the AT 1a R. GABARAP also stimulates the AngII-mediated phospho-ERK1/2 signalling pathway induction. Cell-penetrating peptides, which were designed to block the AT 1 R-GABARAP interaction, effectively reduced intracellular accumulation of the AT 1 R, cell-surface expression and signalling [95] .
Likewise, the biological activities of the endogenous RAS peptide Ang-(1-7) is mediated through inactivation of the PI3K/Akt, p38 MAPK and JNK signalling pathways [81] . Ang-(1-7) and its receptor Mas have antiproliferative properties. For instance, Ang-(1-7) inhibits both the growth of human lung cancer cells in vitro and tumour angiogenesis in vivo through activation of the Mas receptor. Antimetastatic, antimigration and anti-invasion effects of the Ang-(1-7) peptide in A549 human lung adenocarcinoma cells has been demonstrated [81] . Ang-(1-7) also has a role in the mobilization of haematopoietic cells [29, 32] .
Ang-(1-7) is a pleiotropic heptapeptide hormone with dual actions. Ang-(1-7) has antiproliferative effects on cancer cells, but paradoxically has a pro-mobilization effect on haematopoietic cells. Ang-(1-7) stimulates haematopoietic recovery after irradiation, as, for example, in vivo studies have shown that angiotensin peptides increase haematopoietic recovery after myelosuppression [48, 49, 96] . The myelosuppressive therapies evaluated included TBI and intravenous administration of two different chemotherapeutic agents. The increases were most profound and longest lasting in the BM, consistent with the observed effects on early progenitors and effects on blood cell lineages, including observed increases in red blood cell [BFU-E (burst-forming unit erythroid)] and platelet [CFU-Meg (colony-forming cells megakaryocyte)] progenitors after Ang-(1-7) treatment. In addition, Ang-(1-7) stimulates dendritic cell function and plays a role in maturation of human dendritic cells [48, 49, 96] . The exact mechanism for the contradictory cellular effects of Ang-(1-7) is unknown. However, Ang-(1-7) alters the concentration and the balance between proliferative and antiproliferative prostaglandins [97] . Since AngII also utilizes eicosanoid pathways, the paradoxical cellular events might be ascribed to the dual effects on prostanoids.
RAS and other essential pathobiological events of oncogenesis: angiogenesis, inflammation, genomic aberrations and immunological dysregulation Angiogenesis plays a pivotal role in tumour development, and the local RAS contributes to the promotion of tumour angiogenesis. AngII can play an augmentory role in the expression of VEGF (vascular endothelial growth factor), the main stimulator of pathological vessel formation [98] . The inhibitory effect of the ACEI benazepril on the growth of oesophageal carcinoma xenografts has been shown. The potential mechanism of benazepril action may be the suppression of tumour vessel formation via inversely affecting VEGF expression [99] . Likewise, the blockade of the RAS by ACEIs or ARBs markedly attenuated HCC (hepatocellular carcinoma) along with suppression of angiogenesis [100] . Similar effects regarding the RAS and tumour angiogenesis have been described in breast cancer and other malignant diseases [79, 98, 101, 102] . Inflammation, together with neo-angiogenesis, represents the point of cross-talk between the local RAS and carcinogenesis. AngII increases vascular permeability via the release of prostaglandins and VEGF or the re-arrangement of cytoskeletal proteins [103] . Thus AngII is involved in the key initiative events of the cancer-associated inflammatory process, cell growth and matrix synthesis. Furthermore, AngII could contribute to the recruitment of inflammatory cells into the cancer tissue through the regulation of adhesion molecules and chemokines by resident cells. RAS activation also plays a role in the immunologically induced inflammation and transcriptional regulation, predominantly via NF-κB and AP-1 (activator protein-1) activation [80, 103] .
The influence of ACE gene polymorphism on gastric cancer progression has been investigated [104] . ACE is expressed locally in gastric cancer and the gene polymorphism is associated with metastatic behaviour. ACE genotypes correlate with the number of lymph node metastases and the UICC (Unio Internationale Contra Cancrum) tumour stage. In that study, gastric cancer patients with the I/I (insertion/insertion) genotype had a highly significant smaller number of lymph node metastases and a significantly lower UICC tumour stage (P = 0.01) than patients with the D/D (deletion/deletion) genotype [104] . Germline and somatic mutations leading to dysregulation of the local RAS may promote tumour progression in solid tumours such as breast cancer, lung cancer and cancer of the stomach [80, [105] [106] [107] . AT 1 Rs and AT 2 Rs are expressed locally in gastric cancer and the combination of AT 1 R expression and the ACE I/D gene polymorphism correlates with nodal spread in intestinal type gastric cancer [108] . The D/D genotype of ACE may contribute to a higher risk of developing squamous cell lung carcinoma [109] . AngII may trigger activating signals that contribute to cancer cell extravasation and metastasis [110] .
Pre-treatment of cancer cells with AngII increases the number of mice with metastases, as well as the number and size of metastases per mouse. In vitro, AngII contributes to each sequential step of cancer metastasis by promoting cancer cell adhesion to endothelial cells, transendothelial migration and tumour cell migration across the extracellular matrix. At the molecular level, a total of 102 genes differentially expressed following AngII pre-treatment were identified by comparative DNA microarray [110] . AngII regulates two groups of connected genes related to its precursor angiotensinogen. Among those, up-regulated MMP (matrix metalloproteinase) 2/MMP9 and ICAM-1 (intercellular adhesion molecule-1) stand at the crossroads of a network of genes involved in cell adhesion, migration and invasion [110] .
Immunological dysregulation can cause tumour development and progression. T-and NK (natural killer) cells are fully equipped with local RAS elements and are potentially capable of producing and delivering AngII to tissue sites [111] . NK and T-cells express renin, the renin receptor, angiotensinogen and ACE by mRNA analysis. The co-stimulatory effect of AngII and anti-CD3-stimulated T-and NK cell proliferation with AngII treatment were reported. AT 1 R and AT 2 R expression was found in monocytes, NK cells and T-cells. These receptors were functional in immunological events such as calcium signalling, chemotaxis and proliferation [111] . Dendritic cell differentiation is controlled by AngII [74] . Impaired functions of dendritic cells deficient in AT 1 Rs have been shown [72] . AT 1 Rs control the differentiation and functionality of dendritic cells and have a crucial impact on cellular immune processes where local angiotensinergic systems are activated.
Bernstein's group has described a unique mouse model called ACE 10/10, expressing high levels of ACE in macrophages, but lacking ACE in blood vessels and kidney [112] . They studied six groups of mice implanted with B16-F10 melanoma, an aggressive and commonly used tumour model: ACE 10/10 mice, wild-type mice, both ACE 10/10-and wild-type mice treated with the ACEI captopril, and both ACE 10/10 and wild-type mice treated with the ARB losartan. They observed that ACE 10/10 mice have a marked resistance to the growth of B16 melanoma. ACE 10/10 mice respond to melanoma challenge with an enhanced inflammatory response, including increased tumourspecific CD8
+ T-cells. ACE 10/10 mice treated with captopril had a more rapid growth of the melanoma compared with untreated ACE 10/10 mice. Likewise, the angiotensinogen/ACE 10/10-double-KO mice resisted B16-F10 tumours much more effectively than angiotensinogen/ACE wild-type mice (P < 0.0005). Direct transfer of macrophages or the engraftment of wild-type mice with BM from ACE 10/10 mice transferred B16 tumour resistance [112] . Thus their experiments suggested that it is the presence of ACE, and not its absence, that is important in the resistance of ACE 10/10 mice to melanoma growth. They concluded that the resistance to melanoma in ACE 10/10 mice is mediated by immunological mechanisms and not by aberrant AngII production [112] . The same group also reported that ACE is a major peptidase involved in MHC class I antigen processing [113] . On the basis of their outstanding experiments, it was shown that (i) ACE expression is increased with APC maturation, (ii) ACE affects surface MHC class I expression, (iii) ACE edits the MHC class I peptide repertoire, (iv) ACE edits self-antigens, (v) ACE affects the presentation of viral antigens, and (vi) ACE works as a carboxyl dipeptidase on proteasome products, and thus, ACE depletion or ACE overexpression changes immunogenicity [113] . AngII is the most important product of ACE and most of the effects of AngII are mediated by the AT 1 R.
THE LOCAL BM RAS IN NEOPLASTIC HAEMATOPOIESIS Renin
The relevance of renin expression as an aberrant leukaemic marker in acute leukaemia has been proposed by real-time PCR analyses. Renin-like enzyme activity converting angiotensinogen into AngI has been detected in leukaemic blast cells [44, 114, 115] .
A specific immunoreactive renin-like peptide of 47 kDa was isolated from AML (acute myeloid leukaemia) blast cells. Renin is expressed in some myeloid human leukaemia cell lines, such as K562, KU812 and MEG-01 [41] . Multipotential haematopoietic malignant K562 leukaemic blast cells also exhibit significant expression of angiotensinogen and ACE [45] . When K562 cells were treated with inducers of growth inhibition and/or differentiation, renin expression did not disappear, indicating that its expression is associated with a blastic phenotype, rather than with cell proliferation [41] . Casares et al. [41] demonstrated that some myeloid blast cells express renin, but normal BM does not display this expression. They observed renin expression in cells from AML, CML (chronic myeloid leukaemia) and ALL (acute lymphoid leukaemia). The highest frequency was observed in AML patients (47.2 % of the cases). Renin expression disappeared during the complete remission of AML [41] . Inigo and co-workers [42] analysed 76 samples from patients with AML, with follow-up of positive patients. A total of 31 patients (41 %) were positive for renin gene expression at diagnosis. All renin-positive patients at diagnosis showed no expression during complete remission, but expression recurred in those experiencing relapse and persisted when the disease was refractory to treatment [42] .
The chimaeric protein NUP98 (Nucleoporin 98)-HOXA9 (NUP98-homeobox A9) is a prototype of several NUP98 fusions that occur in AML and myelodysplastic syndromes. NUP98-HOXA9 affects the differentiation, proliferation and gene expression of primary human CD34 + haematopoietic cells. NUP98-HOXA9 can increase the numbers of erythroid precursors and impairs both myeloid and erythroid differentiation. Increased renin gene activity was detected during NUP98-HOXA9 enhanced blast formation [116, 117] .
ACE
The presence of ACE in human haematopoietic stem cells throughout haematopoietic ontogeny indicates that primitive haematopoiesis [21] [22] [23] [24] represents the role of the ACE molecule in neoplastic haematological disorders involving neoplastic haematopoiesis. The existence of ACE in human primitive lymphohaematopoietic cells, and embryonic, fetal and adult haematopoietic tissues [21] [22] [23] [24] draws attention to the effects of RAS on neoplastic tissues. Immunohistochemical studies have shown the possible role of ACE/RAS in BM by evaluating ACE expression in normal BM, several myeloproliferative disorders and myelodysplasia [51] . ACE and p53 expression were detected in CD34
+ cells in patients with acute leukaemia during and after the induction of chemotherapy [43] . ACE-expressing macrophages in the lymph nodes of patients Hodgkin's disease have been detected [118] . ACE activity was also linked to multiple myeloma [119, 120] . ACE hyperfunction results in faster hydrolysis of the AcSDKP peptide, which in turn decreases in BM tissues, allowing HSCs to enter the S-stage of the cell cycle [4, 16, 34] . The plasma concentration of AcSDKP, a reversible negative regulator of the proliferation of normal haematopoietic stem cells, is physiologically regulated by ACE [14] [15] [16] 121] . In vitro incubation of AML cells with an ACEI decreased the growth and colony-forming ability of AML cells in a dose-dependent manner. Addition of the AngII peptide to AML cells partially rescued their colony-forming ability [121] . Overexpression of ACE-surface antigen in leukaemic myeloid blast cells has been detected by flow cytometric analyses. Moreover, a positive correlation has been found between ACE and BM blast count [35] . We investigated ACE I/D gene polymorphisms in patients with haematological malignancies, including acute and chronic leukaemia, myelodysplastic syndrome and multiple myeloma. Our results showed that 80.4 % of the patients had a ID/II genotype compared with 55.9 % in the control group, with a 3.2-fold increased disease risk in the presence of the insertion allele (ID/II) [122] .
Angiotensinogen
We found that human UCB cells express renin, angiotensinogen, and ACE mRNAs [123] . Angiotensinogen, ACE and renin mRNA expression are increased in PRV [40] . Leucocytes also express the angiotensinogen gene, synthesizing and releasing angiotensinogen, with the capability of generating angiotensin [54] . CML patients had increased ACE, angiotensinogen and renin mRNA levels and these expression levels decreased following the administration of imatinib. The expression of RAS components were studied in patients with CML at the time of diagnosis and at 3, 6 and 12 months after diagnosis by quantitative real-time PCR. De novo CML patients had increased ACE, angiotensinogen and renin mRNA levels, and these expression levels decreased following administration of imatinib. The RAS activities were significantly different among Sokal risk groups of CML, highlighting the altered biological activity of RAS in neoplastic disorders. Therefore the haematopoietic RAS affects neoplastic cell production, which may be altered via administration of tyrosine kinase inhibitors such as imatinib [124] .
Angiotensin peptides
AT 1a Rs are present on human CD34 + CD38 − cells, CD34 + CD38 + cells, lymphocytes and stromal cells. AngII, the main effector peptide of the RAS, increased haematopoietic progenitor cell proliferation by acting on AT 1a Rs present on CD34 + HSCs [27] . AngII utilizes the JAK/STAT pathway [18] . Ang-(1-7) contributes to haematopoietic cell proliferation as well [48, 49, 55, 56] . AngII, through interaction with AT 1 Rs, enhances erythroid differentiation in the BM [61] . AngII was found to be acting as an autocrine growth factor for AML [46] . The RAS member AGTRAP is important in haematopoietic cell proliferation and survival and has a synergistic effect with the proliferation-promoting function of thrombopoietin receptor Mpl [9] . BM AT 1 R expression levels of myeloma patients had a positive correlation with their BM infiltration pattern and tumour load, indicated by serum β 2 -microglobulin levels [120] . AT 1a Rs in BM cells participates in the pathogenesis of atherosclerosis, as shown by analysing several BM chimaeric mice whose BM cells were positive or negative for AT 1a Rs. AT 1a Rs expressed on BMderived cells plays a role in the pathogenesis of atherosclerosis by accelerating infiltration of BM-derived inflammatory cells in the vessel wall. Blockade of AT 1 Rs not only in vascular cells, but also in BM, can be an important strategy to prevent progression and destabilization of atherosclerotic plaques. Therefore the effects of local RAS on the pathobiology of atherosclerosis give very important clues to better understand the effects of the local haematopoietic RAS on the development of neoplastic disorders [52, [125] [126] [127] [128] [129] [130] [131] [132] [133] . The comparable proliferative functions of the local RAS throughout the human body (including the myocardium, pancreas, pituitary gland, ovary and kidney) in health and disease represent the true basis for the design of future experimental studies to test this hypothesis [4] . Figure 3 gives an overview of the contribution of the RAS components to primitive and neoplastic haematopoiesis.
FUTURE PERSPECTIVES
The local tissue RAS, including the local haematopoietic BM RAS [4] , is active from embryogenesis [22] to aging [134] . Therefore targeting the actions of the local RAS may represent a valuable therapeutic option for the management of neoplastic disorders [135] . Current medical practice includes RAS-modulating drugs for the management of cardiovascular disorders. The effects of RAS blockers on circulating RAS are well known, but their effects on the genesis and progression of cancer are conflicting [50, [136] [137] [138] [139] . Future therapeutic designs for the alteration of the local BM RAS should focus on locally active molecules. For instance, the tetrapeptide AcSDKP acts as an inhibitor of primitive haematopoietic cell proliferation and induces angiogenesis in BM stroma. Therefore goralatide can be suggested as a possible therapeutic application in a variety of states of haematopoiesis [140] . AT 1 R antagonists impair the in vivo AngII-related angiogenesis of BM mesenchymal stem cells by inactivation of the AT 1a R/PI3K/Akt-related pathway [141] . The pharmacologically developed drug Ang-(1-7) is already in Phase I/II clinical trials for the modulation of the BM RAS in distinct disease states [33, 48, 49] . However, since most of the cellular effects of the local RAS are via autocrine, paracrine and intracrine pathways, future drugs intended to modulate local RAS functions should be prepared to have local targeted actions in the tissue micro-environment, such as inside the BM. For instance, Kawabata et al. [142] recently formulated a nanoparticle vector (dTAT NP) to leverage the efficiency of this cell-penetrating strategy for tumour-targeted gene delivery in the setting of intratracheal administration. They found that bolus administration of dTAT NP-encapsulated AT 2 Rs or TRAIL (TNF-related apoptosis-inducing ligand) cDNA markedly attenuated tumour growth. Thus they suggested a novel gene delivery system that offers an effective intratracheal strategy for administering lung cancer gene therapy [142] .
Future experimental and clinical studies are needed to elucidate the puzzling functions of the local tissue RAS, including the local BM RAS. These efforts should focus on dissecting local RAS interactions with the complicated pathobiological characteristics of neoplastic disorders and on manipulating autocrine/paracrine/intracrine systems for the better clinical management of patients with cancer.
